Global Thalassemia Drugs Market 2018-2022

The global thalassemia drugs market is predicted to reach a size of more than USD 3.42 billion by 2022. Wondering how to make the most of this booming industry? Technavio’s extensive industry research report offers a detailed insight that will allow you to take full advantage of the opportunities available to you. This study provides an in-depth analysis of the market by drug type and by region. It also examines the competitive landscape and manufacturers of products for treatment of thalassemia that include ApoPharma, Fresenius Kabi, and Novartis.

Check out insights about the thalassemia drugs industry and treatment of thalassemia

The global thalassemia drugs market is expected to expand at a CAGR of more than 10% during the forecast period

Thalassemia drugs industry growth is expected to accelerate over the next five years, driven by increasing prevalence of this disease which has no cure and can only be treated. APAC will drive more than 38% of the growth of the thalassemia drugs industry, while EMEA and the Americas are also predicted to make significant contributions to the incremental growth in the forecast period. APAC held the largest market share in 2017 due to a high prevalence of thalassemia disease in the Asian population. Furthermore, APAC is geared to maintain their dominant position in the global thalassemia drugs market at the end of the forecast period, while EMEA and the Americas will witness a slight decline in the same period. Technavio’s thalassemia drugs industry analysis reveals promising markets around the world.

Want a bigger picture? Get a free sample of this report now!

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.

Increasing prevalence of thalassemia is driving the demand for treatment of thalassemia

The growing prevalence of thalassemia across the world is likely to augment the growth of thalassemia drugs market during the period of forecast. Also, the increasing levels of disposable income in developing economies is also expected to boost the demand for thalassemia drugs. Around 100,00 children are born with thalassemia every year worldwide, out of which 10,000 are born in India, and this increasing prevalence of the disease is going to contribute to the growth of the thalassemia drugs market in the next five years.

Get more value with Technavio’s subscription platform! Gain easy access to all Technavio’s reports, along with on-demand services.      Start your 14-day FREE trial

ApoPharma, Fresenius Kabi, and Novartis are among the leading thalassemia drug manufacturers in the world

Most of the leading vendors in the global thalassemia drugs market are focused on increasing the number of pipeline molecules for the treatment of thalassemia to fulfill the growing demand for thalassemia drugs around the world. Thalassemia is an emerging health concern across the world, and South Asia is a major hub for hemoglobinopathies which is going to drive the growth of demand for treatment of thalassemia over the next few years. Many international and regional vendors are vying for their share of the market, and players must differentiate themselves to gain vital traction over their peers.

This report offers a complete analysis of several companies, including:

• ApoPharma
• Fresenius Kabi
• Novartis
• Pfizer
• Teva Pharmaceutical Industries

Want to dial in on a specific region or segment? We can help! Our analysts can customize this report to meet your requirements.     Get in touch